FDA Putting Dollars into Regulatory Science and more
Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA.
House Appropriations Committee Marks Up Ag/FDA Appropriations Bill. On May 29, the House Appropriations Committee marked up the Ag/FDA bill that had been reported by the subcommittee on May 22. The Committee Report on the bill can be viewed if you click here; a center-by-center comparison of funding levels in the House and Senate bills has also been made available. Today’s Analysis and Commentary looks at the House and Senate bills and discusses funding priorities and oversight issues raised by both committees. As a complement to this, the FDA Law Blog has an excellent summary of the many program issues raised in the House and Senate reports.
House and Senate Floor Action on Ag/House Appropriations? To the best of our knowledge, neither committee-passed bill has been scheduled for floor time. However, the general expectation is that they will be considered by both bodies in June, conferenced in July (or sooner), with final passage before the August recess.
FDA Putting Dollars into Regulatory Science. On May 22, the FDA announced that it intends to provide up to $38 million over 5 years for the Duke University Translational Medicine Initiative. Most of the funding will support the Clinical Trials Transformation Initiative (CTTI), which is designed to increase the quality and efficiency of clinical trials. In a separate and unrelated announcement, the FDA issued its funding priorities and solicited proposals for regulatory science projects that it will fund in FY 15, assuming adequate funds are available.